Plain-English translation of NCT07071155 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing — a new medication — combined with (a drug that changes how cells behave) for patients with rare blood disorders called myelodysplastic syndromes, myeloproliferative overlap neoplasms, or chronic neutrophilic leukemia. The study will enroll up to 18 patients and start by testing lower doses in the first three participants to make sure the medication is safe before other patients join.
These rare blood disorders are difficult to treat and can cause an enlarged spleen, fatigue, and serious complications. This medication combination may help control the disease by working on specific proteins in blood cells, and researchers want to find the safest and most effective dose.
You likely qualify if…
You likely don't qualify if…
You would take a daily pill at home and receive injections on days 1–5 of each 28-day cycle. The first three participants will receive a lower dose; if that is well-tolerated, remaining participants will receive a higher dose. You'll have regular clinic visits for blood tests, imaging to monitor your spleen, and check-ins about side effects and how you're feeling. The study will track whether the treatment shrinks your spleen and improves your blood counts over time.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States